Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)

Institut du Cancer de Montpellier - Val d'Aurelle600 enrolled

Overview

The creation of a prospective clinical-biological base dedicated to peritoneal carcinosis must therefore be able to serve as a support for this essential search for transfer.

The main objective is to improve the knowledge of carcinosis mechanisms to develop a specific treatment. That's why this blood collection and tissue collection is very important for the future, these collection will be permitted to the scientists to develop a research specially for carcinosis.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

600

Conditions

Cancer Peritoneal Carcinosis

Interventions

biological collectionBIOLOGICAL

Blood samples collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression

Tissues collectionsOTHER

Tumours and not tumours tissues will be collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient over the age of 18; * Patient managed for peritoneal carcinosis : digestives origins (pancreatic, gastroesophageal junction, colorectal, bowel) or peritoneum cancer * Patient eligible for a peritoneal carcinosis treatment : at least one (or more) surgery (s) ;chemotherapy or any treatment for this disease * Patient agree will all study procedure : biological samples \& tissues samples * Patient giving informed consent Exclusion Criteria: * Patient not affiliated to Social Protection system * Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons * The level of French is insufficient to consent to the study and to response to the questionnaires * Patient under guardianship * Pregnancy ou breast-feeding women * Patient treated in case of an emergency

Locations (1)

Institut du cancer de Montpellier ICM

Montpellier, France

RECRUITING

Outcomes

Primary Outcomes

Proportion of patients who gave their consent to participate in the study

The proportion of patients who consent to participate in the study among the screened patients

Time frame: Until the study completion: 4 years

Central Contacts

Aurore MOUSSION

CONTACT

467613100 aurore.moussion@icm.unicancer.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.